The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the conditional marketing authorisation of the EU’s first HER2-targeted therapy for biliary tract cancer (BTC). Zanidatamab is an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody. It is recommended as monotherapy for the treatment of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!